Sarepta Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.2B | $1.9B | $1.2B | $933.0M | $701.9M |
| Cost of revenue | $25.5M | — | — | — | — |
| Selling, general & administrative | $491.7M | $557.9M | $481.9M | $451.4M | $282.7M |
| Research and development | $1.5B | $804.5M | $877.4M | $877.1M | $771.2M |
| Operating income | -$699.8M | $218.1M | -$267.8M | -$536.2M | -$459.7M |
| Interest expense | $38.1M | $18.4M | $22.0M | $53.2M | $63.5M |
| Pretax income | -$702.2M | $260.8M | -$520.1M | -$690.0M | -$418.9M |
| Income tax expense | $11.2M | $25.5M | $15.9M | $13.5M | -$168,000 |
| Net income | -$713.4M | $235.2M | -$536.0M | -$703.5M | -$418.8M |
| Balance Sheet | |||||
| Cash and equivalents | $801.3M | $1.1B | $428.4M | $966.8M | $2.1B |
| Current assets | $2.5B | $3.1B | $2.6B | $2.6B | $2.6B |
| Total assets | $3.3B | $4.0B | $3.3B | $3.1B | $3.1B |
| Current liabilities | $1.1B | $731.7M | $653.7M | $619.6M | $452.7M |
| Total liabilities | $2.2B | $2.4B | $2.4B | $2.7B | $2.2B |
| Stockholders' equity | $1.1B | $1.5B | $859.3M | $384.9M | $928.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$205.5M | -$205.8M | -$501.0M | -$325.3M | -$443.2M |
| Depreciation and amortization | $44.5M | $37.7M | $44.4M | $41.9M | $38.0M |
| Stock-based compensation | $123.4M | $184.3M | $182.5M | $233.0M | $113.9M |
| Capital expenditure | $102.0M | $137.0M | $76.1M | $30.8M | $38.5M |
| Free cash flow | -$307.5M | -$342.7M | -$577.1M | -$356.2M | -$481.7M |
| Share repurchases | $25.0M | $0 | $0 | — | — |
Shares outstanding 105.6M · Free float 84.7%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.